Behçet's disease is a complex, multisystem inflammatory disorder characterised by recurrent mucocutaneous lesions, ocular involvement, and vascular, neurological, and gastrointestinal manifestations.
PRINCETON, N.J., July 31, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...
Soligenix Inc.’s phase IIa study of SGX-945 (dusquetide) for treating oral ulcers in those with Behçet's disease showed biological efficacy in the proof-of-concept study. The positive results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback